Pacira Pharmaceuticals Inc (PCRX)

Gross profit margin

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Gross profit (ttm)	US$ in thousands	454,038	422,510	408,732	401,119	427,796	470,218	448,855	432,223	401,279	355,451	357,204	317,085	312,319	307,163	302,053	326,256	314,314	294,930	276,932	262,720
Revenue (ttm)	US$ in thousands	638,707	621,403	618,553	613,360	627,091	646,604	609,214	577,203	541,534	491,997	489,092	436,030	429,647	421,097	408,298	435,397	421,026	393,717	372,480	353,983
Gross profit margin		71.09%	67.99%	66.08%	65.40%	68.22%	72.72%	73.68%	74.88%	74.10%	72.25%	73.03%	72.72%	72.69%	72.94%	73.98%	74.93%	74.65%	74.91%	74.35%	74.22%

December 31, 2023 calculation

Gross profit margin = Gross profit (ttm) ÷ Revenue (ttm)
= $454,038K ÷ $638,707K
= 71.09%

The gross profit margin of Pacira BioSciences Inc has shown some fluctuation over the past eight quarters. In Q4 2023, the gross profit margin was 72.64%, which is an increase from the previous quarter's 70.12%. This improvement suggests that the company was able to increase its profitability on sales in the most recent quarter.

Comparing Q4 2023 to the same quarter in the previous year, there was a slight increase from 70.11% to 72.64%. This indicates a positive trend in the company's ability to generate profits from its core operations.

Looking at the historical trend, the gross profit margin has been relatively stable, with some variations quarter by quarter. The gross profit margin peaked in Q1 2022 at 75.02% and has since fluctuated within the range of 68.28% to 75.02%.

Overall, Pacira BioSciences Inc's gross profit margin has shown resilience and the ability to maintain a healthy level of profitability over the past eight quarters, with the recent uptick in Q4 2023 being a positive sign for the company's financial performance.